Publications by authors named "A Belley"
The observation of neutrinoless double-beta (0νββ) decay would offer proof of lepton number violation, demonstrating that neutrinos are Majorana particles, while also helping us understand why there is more matter than antimatter in the Universe. If the decay is driven by the exchange of the three known light neutrinos, a discovery would, in addition, link the observed decay rate to the neutrino mass scale through a theoretical quantity known as the nuclear matrix element (NME). Accurate values of the NMEs for all nuclei considered for use in 0νββ experiments are therefore crucial for designing and interpreting those experiments.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigated the effectiveness of the new drug combination cefepime/enmetazobactam against Enterobacterales bacteria from Europe, analyzing 2,627 isolates collected between 2019 and 2021.
- - Results showed that 97.9% of tested isolates were susceptible to cefepime/enmetazobactam, with a high prevalence of resistance to third-generation cephalosporins but maintained susceptibility to meropenem.
- - The findings indicate that cefepime/enmetazobactam could potentially serve as a safer alternative to piperacillin/tazobactam for treating infections caused by resistant Enterobacterales strains.
Article Synopsis
- Surfactants, urine, and serum can affect the antibacterial effectiveness of the drug combination cefepime-enmetazobactam (FPE) against lower respiratory infections.
- Various strains of Klebsiella pneumoniae and E. coli were tested to measure the Minimum Inhibitory Concentration (MIC) and the effects of surfactants
- Results showed that lung surfactants and other body fluids did not affect the antibacterial activity of FPE, indicating it remains effective in those conditions.
Article Synopsis
- Cefepime/enmetazobactam is a new antibiotic and β-lactamase inhibitor that could treat difficult gram-negative infections; this study aims to see if it's as effective as piperacillin/tazobactam for complicated UTIs and acute pyelonephritis.
- The research involved a large, double-blind phase 3 clinical trial across 90 global sites, recruiting over 1,000 adult patients diagnosed with specific gram-negative infections.
- The main goal was to measure treatment success, defined as clinical improvement and infection clearance, using a noninferiority margin of -10% to compare outcomes between the two antibiotic groups.